tirzepatide shortage over Lilly, Novo Fight Weight Loss Drug Compounders FDA: Shortage of Weight Loss

The GLP-1 Breakthrough: A Cardiologists Secrets to Lasting Weight Loss and a Healthier Heart

What they found was cost dominates treatment decisions: 68% said cost influenced their decision to start or continue treatment 44% said the medication cost more than they expected Cost surpassed side effects as the #1 reason people stopped taking GLP-1s A breakdown of the financial burden: 24% pay more than $250 per prescription fill Nearly 8% pay $500 or more per fill 24% said insurance didn't cover any cost Weight management patients were nearly twice as likely to pay $250+ vs diabetes patients --- Here's what patients are thinking: Nearly 40% ended up using discount programs or manufacturer coupons 60% know someone who wants GLP-1s but can't afford them 83% believe Americans turn to DTC programs because traditional healthcare is too expensive Patients still prioritize safety: 60% are aware of safety risks with non-FDA-approved GLP-1s--this one surprised me

Choose your standard consent pathway (semaglutide or tirzepatide) and define when each optional addendum is used

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Liana M

Mechanism of action